#1 Clinical Trials Search in Europe

Lovo-B

This article discusses the use of Lovo-B, a component of the investigational drug STC-1010, in clinical trials for patients with advanced or metastatic colorectal cancer. STC-1010 is being studied in combination with standard-of-care therapies to evaluate its safety and efficacy in treating this challenging form of cancer.

Table of Contents

What is STC-1010?

STC-1010 is a new type of cancer treatment called immunotherapy[1]. It is currently being studied as a potential treatment for advanced colorectal cancer. STC-1010 is also known as “Stimulated Tumor Cells-1010,” which gives us a clue about how it works.

How does STC-1010 work?

STC-1010 is made up of specially prepared cancer cells. These cells come from different types of colorectal cancer cell lines, including HCT116, HT-29, and LOVO[1]. The idea behind this treatment is to “stimulate” or activate your immune system to fight against colorectal cancer cells in your body.

Think of it like showing your immune system a “wanted poster” of the cancer cells. By exposing your immune system to these stimulated tumor cells, the hope is that it will learn to recognize and attack similar cancer cells in your body.

What conditions does STC-1010 treat?

STC-1010 is being studied for the treatment of unresectable locally advanced or metastatic colorectal cancer[1]. Let’s break down what this means:

  • Unresectable: This means the cancer cannot be completely removed by surgery.
  • Locally advanced: The cancer has spread from where it started to nearby tissue or lymph nodes.
  • Metastatic: The cancer has spread to other parts of the body, far from where it started.
  • Colorectal cancer: This is a cancer that starts in the colon (large intestine) or rectum.

Clinical Trial Details

The clinical trial for STC-1010 is called the “BreAK CRC trial”[1]. It is divided into two main parts:

  1. Phase I: This part of the trial aims to test the safety of STC-1010 and find the right dose to use.
  2. Phase IIA: This part will test how well STC-1010 works in treating colorectal cancer.

In both phases, STC-1010 will be given along with other cancer treatments. These include chemotherapy drugs (like FOLFOX) and a drug called bevacizumab, which helps stop tumors from growing new blood vessels[1].

Who can participate in the trial?

The trial is looking for adults aged 18-75 with advanced colorectal cancer. There are specific requirements for participation, including[1]:

  • Having a type of colorectal cancer that can’t be removed by surgery
  • Being in overall good health besides the cancer
  • Having normal blood cell counts and organ function
  • Not having certain other medical conditions

It’s important to note that there are many other specific criteria that doctors use to determine if someone is eligible for the trial. If you’re interested in participating, you should discuss this with your oncologist.

Potential Benefits and Risks

As with any experimental treatment, there are potential benefits and risks to participating in this trial:

Potential benefits:

  • Access to a new treatment that might be more effective than current options
  • Close monitoring by a team of medical professionals
  • Contributing to medical research that could help future cancer patients

Potential risks:

  • Unknown side effects from the new treatment
  • The treatment might not be effective
  • Time commitment for treatments and follow-up appointments

It’s crucial to discuss these potential benefits and risks with your healthcare team before deciding to participate in any clinical trial.

Aspect Details
Drug Name STC-1010 (including Lovo-B as an active substance)
Trial Phase Phase I/IIA
Target Condition Unresectable locally advanced or metastatic colorectal cancer
Trial Design Open-label, multicenter, dose-escalation and cohort-expansion
Combination Therapy STC-1010 with standard-of-care treatments (e.g., mFOLFOX6 + bevacizumab)
Primary Endpoints Safety profile, determination of recommended Phase 2 dose, progression-free survival at 12 months
Key Eligibility Criteria Adults 18-75 years, specific tumor characteristics, adequate organ function
Treatment Duration Induction phase (up to 8 cycles) followed by maintenance therapy

FAQ

  • What is Lovo-B and how is it being used in clinical trials? Lovo-B is one of the active substances in STC-1010, an investigational immunotherapy drug. It's being tested in clinical trials for patients with advanced or metastatic colorectal cancer, in combination with standard treatments like chemotherapy and other targeted therapies.
  • Who is eligible to participate in these clinical trials? Eligible participants are adults aged 18-75 with unresectable locally advanced or metastatic colorectal cancer. They must meet specific criteria regarding their overall health, cancer type, and previous treatments. Some trials focus on patients with specific genetic markers in their tumors.
  • What are the main objectives of these clinical trials? The primary objectives are to assess the safety of STC-1010 (which includes Lovo-B) when combined with standard treatments, determine the appropriate dose, and evaluate its effectiveness in treating advanced colorectal cancer.
  • How long do these clinical trials last? The duration varies, but the trials typically involve an induction phase of up to 8 cycles of treatment, followed by a maintenance phase. Participants are monitored for at least 12 months to assess progression-free survival.
  • Are there any specific side effects or risks associated with Lovo-B or STC-1010? As this is an investigational treatment, all potential side effects are not yet known. The trials closely monitor participants for any adverse events. Common side effects of cancer treatments may include fatigue, nausea, and changes in blood cell counts. Specific risks related to Lovo-B will be determined through these studies.

Ongoing Clinical Trials on Lovo-B

  • Study on STC-1010 and Drug Combination for Patients with Advanced or Metastatic Colorectal Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

Glossary

  • Unresectable: A tumor that cannot be completely removed through surgery due to its size, location, or spread.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer cells.
  • Standard of Care (SOC): The currently accepted and widely used treatment for a specific condition.
  • mFOLFOX6: A chemotherapy regimen commonly used to treat colorectal cancer, consisting of multiple drugs.
  • Bevacizumab: A targeted therapy drug that works by blocking the growth of blood vessels that feed tumors.
  • MSS/pMMR: Microsatellite Stable/proficient Mismatch Repair, referring to specific genetic characteristics of some colorectal cancers.
  • MSI-H/dMMR: Microsatellite Instability-High/deficient Mismatch Repair, genetic features associated with some colorectal cancers that may respond differently to certain treatments.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, a standardized method to assess how tumors respond to treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the cancer getting worse.

References

  1. http://clinicaltrials.eu/trial/study-on-stc-1010-and-drug-combination-for-patients-with-advanced-or-metastatic-colorectal-cancer/